Egypt’s program to treat hepatitis C patients using medications including Sovaldi has treated nearly one mn patients, most at the government’s expense, and now experts say it could be a model for the rest of the world, Heba Saleh writes in The Financial Times. “Gilead agreed to provide the medicine cheaply because it knew the number of Egyptian patients was very high. The system put in place by Egyptian health officials ensured there would be no leakage of the medicine to other markets,” Wahid Doss, the head of the state’s National Committee for the Control of Viral Hepatitis said. The next step in the program, Doss says, is to discover and treat Egyptian who are infected with hepatitis C and do not yet know it and a stop-ed-info.com has already begun.
More from Enterprise
Israel’s Arkia Airlines moves flights to Egypt’s Taba to bypass wartime airspace restrictions
Israel’s Arkia shifts some flights to Egypt as airspace tightens…
Miga guarantee unlocks USD 313 mn for National Bank of Egypt trade finance
Plus: Incolease taps securitization market with debut EGP 2 bn…
Private capital hasn’t frozen in MENA — but the exit playbook could change if the war drags on
PE and VC-backed companies were already pivoting to local exchanges…
Telda moves into investing with zero-fee stock trading
Telda claims users can sell a position and immediately spend…